Meet the innovators working out of The Cannon Houston's brand new space

Houston innovators podcast episode 5

This week's episode of the Houston Innovators Podcast highlights 11 different entrepreneurs at a live recording at The Cannon Houston's grand opening event. Courtesy of Quy Tran/The Cannon

Last week, The Cannon Houston premiered its new digs in West Houston with a grand opening event attended by an incredible group of innovators, entrepreneurs, friends, family, and even puppies.

InnovationMap and the Houston Innovators Podcast had a presence at the festivities as well, which has allowed us to put together a special edition of the podcast. Rather than recording an interview with one entrepreneur in studio, this week's episode features 11 interviews with over a dozen innovators.

Here's who all you'll hear from — in order — in this episode:

  • Werner Winterboer of SapMok, a South African sustainable shoe making company that's looking to expand in Houston.
  • Brad Greer of DrySee, a liquid bandage company that's created a wetness indicator that allows for a patient to know if their bandage has been compromised thus preventing infection risks.
  • Chris Bayardo of Bayardo Safety LLC, a small compliance company that uses tech to optimize the oil and gas industry's compliance issues.
  • Dirk Van Slyke of Statistical Vision, a marketing consultancy that taps into data and metrics to help organizations take their company to the next level.
  • Aaron Knape of sEATz, an app that has perfected the mobile food and drink ordering process in stadiums.
  • Matt and Adam Woods of Skippermyboat, a tourism startup that helps travelers easily connect with boating adventures all over the world.
  • Mike T. Brown of Win-Win, a sports tech company that gamifies the donation process for causes supported by professional athletes.
  • Alex Taghi, Aimee Robert, and Jeffery Abel of Co-Counsel, the coworking concept for lawyers and attorneys.
  • Jeff Miller of Potentia, an education and staffing platform that helps place autistic employees with their right employer.
  • Drew Wadley with MiTyket, which has created a software that can prevent price gouging in the live entertainment industry.
  • Bret Bloch with Four Tower LLC, which provides integrated solutions for projects and operations.

Check out the episode below and subscribe wherever you get your podcasts.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”